CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$7.06M |
| 3 |
NVIDIA
NVDA
|
$6.46M |
| 4 |
Microsoft
MSFT
|
$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
$5.72M |
| 2 |
GSK
GSK
|
$5.14M |
| 3 |
Pinduoduo
PDD
|
$3.46M |
| 4 |
Procter & Gamble
PG
|
$2.91M |
| 5 |
Synopsys
SNPS
|
$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
Biomea Fusion
BMEA
$114M
| $29.8K | ﹤0.01% |
7,684
+720
| +10% | +$2.79K |
|
477
Align Technology
ALGN
$10.1B
| $27.7K | ﹤0.01% |
133
| – | – |
|
478
PepGen
PEPG
$45.9M
| $26.2K | ﹤0.01% |
+6,911
| New | +$26.2K |
|
479
Enanta Pharmaceuticals
ENTA
$189M
| $25.8K | ﹤0.01% |
+4,494
| New | +$25.8K |
|
|
CLYM
480
Climb Bio, Inc. Common Stock
CLYM
$162M
| $25.7K | ﹤0.01% |
+14,254
| New | +$25.7K |
|
|
OKUR
481
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $23.1K | ﹤0.01% |
2,683
+2,040
| +317% | +$17.5K |
|
482
Editas Medicine
EDIT
$248M
| $22.2K | ﹤0.01% |
17,503
+1,640
| +10% | +$2.08K |
|
483
Applied Therapeutics
APLT
$68.2M
| $21.1K | ﹤0.01% |
+24,672
| New | +$21.1K |
|
484
Quanterix
QTRX
$211M
| $20.1K | ﹤0.01% |
1,894
-83,125
| -98% | -$884K |
|
485
Pyxis Oncology
PYXS
$118M
| $19.7K | ﹤0.01% |
+12,609
| New | +$19.7K |
|
486
Edwards Lifesciences
EW
$47.5B
| $19K | ﹤0.01% |
256
| – | – |
|
487
Repligen
RGEN
$7.01B
| $16.6K | ﹤0.01% |
115
| – | – |
|
488
Charles River Laboratories
CRL
$8.07B
| $16.4K | ﹤0.01% |
89
| – | – |
|
489
Exact Sciences
EXAS
$10.2B
| $12.1K | ﹤0.01% |
216
| – | – |
|
490
SPDR S&P Dividend ETF
SDY
$20.5B
| $9.91K | ﹤0.01% |
+75
| New | +$9.91K |
|
491
Q32 Bio
QTTB
$20.4M
| $8.89K | ﹤0.01% |
+2,583
| New | +$8.89K |
|
492
iShares 20+ Year Treasury Bond ETF
TLT
$48.9B
| $8.47K | ﹤0.01% |
+97
| New | +$8.47K |
|
493
Huazhu Hotels Group
HTHT
$11.5B
| $6.61K | ﹤0.01% |
200
| – | – |
|
494
Foot Locker
FL
$2.29B
| $2.18K | ﹤0.01% |
100
| – | – |
|
495
Hershey
HSY
$37.6B
| $1.69K | ﹤0.01% |
10
| – | – |
|
496
PVH
PVH
$4.22B
| $846 | ﹤0.01% |
8
-2,990
| -100% | -$316K |
|
497
ATAI Life Sciences
ATAI
$980M
| – | – |
-32,273
| Closed | -$37.4K |
|
498
Aclaris Therapeutics
ACRS
$227M
| – | – |
-13,722
| Closed | -$15.8K |
|
499
ALX Oncology
ALXO
$65.3M
| – | – |
-10,130
| Closed | -$18.4K |
|
500
Cabaletta Bio
CABA
$155M
| – | – |
-9,395
| Closed | -$44.3K |
|